Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KIRIM-KONGO-VAX
- Development stage
- Phase 1
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
KIRIM-KONGO-VAX is a candidate vaccine developed for the prevention of Crimean-Congo hemorrhagic fever (CCHF), a severe tick-borne viral disease caused by the CCHF virus, which belongs to the Nairovirus genus in the Bunyaviridae family. The vaccine entered phase I clinical trials between December 2014 and June 2017, but as of now, no results have been published regarding its efficacy or safety. The specific mechanism of action has not been publicly detailed; however, CCHF vaccines under development typically use viral vectors or inactivated virus platforms to induce immune responses targeting key viral proteins such as nucleoprotein (NP) or glycoproteins (GPC). The primary indication for this vaccine is prophylaxis against Crimean-Congo hemorrhagic fever[4].
- Brand names
- KIRIM-KONGO-VAX
- Other names
- KIRIM-KONGO-VAX
Beyond the preview
Go deeper on KIRIM-KONGO-VAX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KIRIM-KONGO-VAX.